Evidence map›Paper›PMID 37456044›Full record

ArticleHeliyon2023

Tricarboxylic acid (TCA) cycle, sphingolipid, and phosphatidylcholine metabolism are dysregulated in

Tzu-Yu Feng, Stephanie J Melchor, Xiao-Yu Zhao, Haider Ghumman, Mark Kester, Todd E Fox, Sarah E Ewald

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. The intersection of hostMicrobiology and molecular biology reviews : MMBR · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tzu-Yu FengDepartment of Microbiology, Immunology, and Cancer Biology and The Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Stephanie J MelchorDepartment of Microbiology, Immunology, and Cancer Biology and The Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Xiao-Yu ZhaoDepartment of Microbiology, Immunology, and Cancer Biology and The Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Haider GhummanDepartment of Microbiology, Immunology, and Cancer Biology and The Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Mark KesterDepartment of Pharmacology at the University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Todd E FoxDepartment of Pharmacology at the University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Sarah E EwaldDepartment of Microbiology, Immunology, and Cancer Biology and The Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
University of Virginia · US

Funding

Innate Inflammatory Control of CachexiaR35GM138381 · NIGMS · UNIVERSITY OF VIRGINIA · PI Sarah E. Ewald · 2020 to 2026
$2.9M
NIGMS NIH HHS R35 GM138381
6 · The paper itself

Abstract

Cachexia is a life-threatening disease characterized by chronic, inflammatory muscle wasting and systemic metabolic impairment. Despite its high prevalence, there are no efficacious therapies for cachexia. Mice chronically infected with the protozoan parasite

Indexed as

CachexiaCeramidesLipid reboundLiver atrophySphingolipidsTCA cycleToxoplasma gondii

Identifiers

PMID37456044
PMCPMC10344712
OpenAlexW4383216839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.